Monte Rosa Therapeutics, Inc.
GLUE
$3.70
-$0.34-8.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 104.55% | 46.29% | 10.15% | -4.07% | -16.02% |
| Total Depreciation and Amortization | 12.17% | 22.82% | 29.01% | 50.32% | 83.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.34% | 21.52% | 16.42% | 14.56% | -9.11% |
| Change in Net Operating Assets | -89.70% | 26.12% | 134.31% | 236.90% | 497.48% |
| Cash from Operations | 159.20% | 195.88% | 41.18% | 34.61% | 33.81% |
| Capital Expenditure | 62.73% | 79.06% | 77.69% | 72.28% | 44.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -100.00% | 487.50% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -267.96% | -137.54% | -86.18% | -86.13% | 4,270.61% |
| Cash from Investing | -297.29% | -150.06% | -96.40% | -109.57% | 526.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,744.18% | 1,914.30% | 109.95% | 124.36% | -86.69% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 86.30% | 86.30% | 10,891.13% | 7,645.02% | 2,628.86% |
| Cash from Financing | 255.92% | 259.71% | 442.60% | 481.03% | 36.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -144.65% | 33.03% | 223.72% | 208.23% | 154.89% |